458870 - Seers Co., Ltd.

458870 Summary

Medical Devices

Stock Price & Overview

₩21,350 +650 (+3.14%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩21,350 ≈ US$15 · Market cap ₩0.8tn (≈ $585m)

458870 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023
Total Revenue	48.2	8.1	1.9
Cost of Revenue	13.3	4.7	2.7
Gross Profit	34.9	3.4	-0.8
Selling, General & Administrative	18.6	12.1	9.0
Operating Income	16.3	-8.7	-9.8
Finance Income	0.2	0.3	0.1
Finance Costs	0.2	0.4	0.2
Pretax Income	16.1	-8.8	-9.9
Income Tax Expense	0.1	0.1	—
Net Income	16.0	-8.9	-9.9
Total Comprehensive Income	16.2	-9.2	-10.0

Breakdown ₩ bn	FY2025	FY2024	FY2023
Total Assets	54.2	28.1	17.1
Current Assets	40.4	16.4	5.9
Cash & Cash Equivalents	11.1	10.8	4.1
Inventories	4.0	1.2	1.0
Trade Receivables	22.0	4.2	0.5
Non-current Assets	13.8	11.6	11.3
Property, Plant & Equipment	11.7	10.2	10.8
Intangible Assets	0.2	0.0	0.0
Total Liabilities	14.6	6.7	9.0
Current Liabilities	10.8	3.9	6.7
Non-current Liabilities	3.8	2.8	2.3
Total Equity	39.6	21.4	8.1
Share Capital	6.3	6.3	5.5
Retained Earnings	-29.0	-45.2	-36.0

Breakdown ₩ bn	FY2025	FY2024	FY2023
Cash from Operating Activities	2.1	-11.1	-7.9
Cash from Investing Activities	-2.0	-1.4	-1.0
Purchase of Property, Plant & Equipment	1.5	0.4	0.7
Cash from Financing Activities	0.2	19.2	2.7
Net Change in Cash	0.3	6.7	-6.2

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2
Total Revenue	28.4	32.5	20.4	15.7	8.0
Cost of Revenue	8.3	11.7	5.0	4.6	2.2
Gross Profit	20.1	20.9	15.4	11.1	5.7
Selling, General & Administrative	7.2	7.0	6.7	4.4	4.3
Operating Income	12.9	13.9	8.7	6.7	1.5
Finance Income	0.1	0.1	0.1	0.1	0.1
Finance Costs	0.1	0.1	0.1	0.1	0.1
Pretax Income	12.9	13.7	8.5	6.7	1.5
Net Income	12.9	13.7	8.4	6.7	1.5
Total Comprehensive Income	12.9	13.7	8.5	6.7	1.5

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2
Total Assets	85.9	73.6	54.2	40.7	31.2
Current Assets	70.7	59.2	40.4	28.2	19.6
Cash & Cash Equivalents	25.9	14.3	11.1	9.5	9.8
Inventories	6.9	4.1	4.0	1.9	1.8
Trade Receivables	32.0	38.5	22.0	15.2	7.5
Non-current Assets	15.1	14.4	13.8	12.5	11.7
Property, Plant & Equipment	12.6	12.1	11.7	10.7	10.0
Intangible Assets	0.2	0.2	0.2	0.1	0.1
Total Liabilities	17.5	19.5	14.6	10.3	8.5
Current Liabilities	13.6	15.6	10.8	6.9	5.6
Non-current Liabilities	4.0	3.9	3.8	3.4	2.9
Total Equity	68.4	54.2	39.6	30.4	22.8
Share Capital	19.0	19.0	6.3	6.3	6.3
Retained Earnings	-2.3	-15.3	-29.0	-37.5	-44.3

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2
Cash from Operating Activities	11.3	4.4	2.8	-0.3	—
Cash from Investing Activities	-1.0	-0.9	-1.1	-0.5	—
Purchase of Property, Plant & Equipment	0.6	0.7	0.8	0.3	—
Cash from Financing Activities	1.2	-0.2	-0.1	0.5	—
Net Change in Cash	11.6	3.2	1.6	-0.3	—

Consolidated (CFS), from DART. 3 fiscal years and 5 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

458870 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	48.2	+494.7%	—	—	—
Operating income	16.3	—	—	—	—
Net income	16.0	—	—	—	—
EPS	₩418	—	—	—	—
Operating cash flow	2.1	—	—	—	—
Shareholders' equity	39.6	+85.2%	—	—	—

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

458870 Profitability

Ratio	FY2025	FY2024	FY2023
Gross margin	72.4%	42.4%	-43.7%
Operating margin	33.9%	-107.2%	-520.1%
Net margin	33.3%	-109.5%	-526.1%
Return on equity	52.6%	-60.1%	-122.3%
Return on assets	39.0%	-39.2%	-57.8%
Operating cash flow / revenue	4.3%	-137.0%	-418.9%
Capex / revenue	3.1%	4.9%	36.5%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 458870

Symbol	Last Price
096530Seegene, Inc.	₩31,900 +1.1%
491000Livs Med, Inc.	₩34,500 +3.6%
041830In Body Co., Ltd.	₩61,100 +2.5%
445680Curiox Biosystems Co., Ltd.	₩47,650 -1.5%
137310SD Biosensor	₩6,160 -0.3%
377740Bio Note, Inc.	₩4,790 -0.2%
340570T & L Co., Ltd.	₩29,650 +1.2%
099190i-SENS, Inc.	₩16,470 +0.0%
336570WON Tech Co., Ltd.	₩4,905 +0.9%
174900Ab Clon, Inc.	₩21,600 +5.9%

Compare all 13 in Medical Devices

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.